Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways

Aleksandra M. Wojtas, Sylvia Kang, Benjamin M. Olley, Maureen Gatherer, Mitsuru Shinohara, Patricia A. Lozano, Chia-Chen Liu, Aishe Kurti, Kelsey E. Baker, Dennis W Dickson, Mei Yue, Leonard Petrucelli, Guojun D Bu, Roxana O. Carare, John D. Fryer

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ) peptide deposition in brain parenchyma as plaques and in cerebral blood vessels as cerebral amyloid angiopathy (CAA). CAA deposition leads to several clinical complications, including intracerebral hemorrhage. The underlying molecular mechanisms that regulate plaque and CAA deposition in the vast majority of sporadic AD patients remain unclear. The clusterin (CLU) gene is genetically associated with AD and CLU has been shown to alter aggregation, toxicity, and blood–brain barrier transport of Aβ, suggesting it might play a key role in regulating the balance between Aβ deposition and clearance in both brain and blood vessels. Here, we investigated the effect of CLU on Aβ pathology using the amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of AD amyloidosis on a Clu+/+ or Clu−/− background. We found a marked decrease in plaque deposition in the brain parenchyma but an equally striking increase in CAA within the cerebrovasculature of APP/PS1;Clu−/− mice. Surprisingly, despite the several-fold increase in CAA levels, APP/PS1;Clu−/− mice had significantly less hemorrhage and inflammation. Mice lacking CLU had impaired clearance of Aβ in vivo and exogenously added CLU significantly prevented Aβ binding to isolated vessels ex vivo. These findings suggest that in the absence of CLU, Aβ clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.

Original languageEnglish (US)
Pages (from-to)E6962-E6971
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number33
DOIs
StatePublished - Aug 15 2017

Fingerprint

Clusterin
Cerebral Amyloid Angiopathy
Amyloid
Drainage
Alzheimer Disease
Amyloid beta-Protein Precursor
Blood Vessels
Brain
Cerebral Hemorrhage
Amyloidosis
Pathology
Hemorrhage
Inflammation
Peptides

Keywords

  • Alzheimer’s disease
  • Cerebral amyloid angiopathy
  • Clusterin
  • Hemorrhage

ASJC Scopus subject areas

  • General

Cite this

Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. / Wojtas, Aleksandra M.; Kang, Sylvia; Olley, Benjamin M.; Gatherer, Maureen; Shinohara, Mitsuru; Lozano, Patricia A.; Liu, Chia-Chen; Kurti, Aishe; Baker, Kelsey E.; Dickson, Dennis W; Yue, Mei; Petrucelli, Leonard; Bu, Guojun D; Carare, Roxana O.; Fryer, John D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 33, 15.08.2017, p. E6962-E6971.

Research output: Contribution to journalArticle

Wojtas, Aleksandra M. ; Kang, Sylvia ; Olley, Benjamin M. ; Gatherer, Maureen ; Shinohara, Mitsuru ; Lozano, Patricia A. ; Liu, Chia-Chen ; Kurti, Aishe ; Baker, Kelsey E. ; Dickson, Dennis W ; Yue, Mei ; Petrucelli, Leonard ; Bu, Guojun D ; Carare, Roxana O. ; Fryer, John D. / Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 33. pp. E6962-E6971.
@article{0c4aefbd278d4c77964890a1ece940e5,
title = "Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways",
abstract = "Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ) peptide deposition in brain parenchyma as plaques and in cerebral blood vessels as cerebral amyloid angiopathy (CAA). CAA deposition leads to several clinical complications, including intracerebral hemorrhage. The underlying molecular mechanisms that regulate plaque and CAA deposition in the vast majority of sporadic AD patients remain unclear. The clusterin (CLU) gene is genetically associated with AD and CLU has been shown to alter aggregation, toxicity, and blood–brain barrier transport of Aβ, suggesting it might play a key role in regulating the balance between Aβ deposition and clearance in both brain and blood vessels. Here, we investigated the effect of CLU on Aβ pathology using the amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of AD amyloidosis on a Clu+/+ or Clu−/− background. We found a marked decrease in plaque deposition in the brain parenchyma but an equally striking increase in CAA within the cerebrovasculature of APP/PS1;Clu−/− mice. Surprisingly, despite the several-fold increase in CAA levels, APP/PS1;Clu−/− mice had significantly less hemorrhage and inflammation. Mice lacking CLU had impaired clearance of Aβ in vivo and exogenously added CLU significantly prevented Aβ binding to isolated vessels ex vivo. These findings suggest that in the absence of CLU, Aβ clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.",
keywords = "Alzheimer’s disease, Aβ, Cerebral amyloid angiopathy, Clusterin, Hemorrhage",
author = "Wojtas, {Aleksandra M.} and Sylvia Kang and Olley, {Benjamin M.} and Maureen Gatherer and Mitsuru Shinohara and Lozano, {Patricia A.} and Chia-Chen Liu and Aishe Kurti and Baker, {Kelsey E.} and Dickson, {Dennis W} and Mei Yue and Leonard Petrucelli and Bu, {Guojun D} and Carare, {Roxana O.} and Fryer, {John D.}",
year = "2017",
month = "8",
day = "15",
doi = "10.1073/pnas.1701137114",
language = "English (US)",
volume = "114",
pages = "E6962--E6971",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "33",

}

TY - JOUR

T1 - Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways

AU - Wojtas, Aleksandra M.

AU - Kang, Sylvia

AU - Olley, Benjamin M.

AU - Gatherer, Maureen

AU - Shinohara, Mitsuru

AU - Lozano, Patricia A.

AU - Liu, Chia-Chen

AU - Kurti, Aishe

AU - Baker, Kelsey E.

AU - Dickson, Dennis W

AU - Yue, Mei

AU - Petrucelli, Leonard

AU - Bu, Guojun D

AU - Carare, Roxana O.

AU - Fryer, John D.

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ) peptide deposition in brain parenchyma as plaques and in cerebral blood vessels as cerebral amyloid angiopathy (CAA). CAA deposition leads to several clinical complications, including intracerebral hemorrhage. The underlying molecular mechanisms that regulate plaque and CAA deposition in the vast majority of sporadic AD patients remain unclear. The clusterin (CLU) gene is genetically associated with AD and CLU has been shown to alter aggregation, toxicity, and blood–brain barrier transport of Aβ, suggesting it might play a key role in regulating the balance between Aβ deposition and clearance in both brain and blood vessels. Here, we investigated the effect of CLU on Aβ pathology using the amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of AD amyloidosis on a Clu+/+ or Clu−/− background. We found a marked decrease in plaque deposition in the brain parenchyma but an equally striking increase in CAA within the cerebrovasculature of APP/PS1;Clu−/− mice. Surprisingly, despite the several-fold increase in CAA levels, APP/PS1;Clu−/− mice had significantly less hemorrhage and inflammation. Mice lacking CLU had impaired clearance of Aβ in vivo and exogenously added CLU significantly prevented Aβ binding to isolated vessels ex vivo. These findings suggest that in the absence of CLU, Aβ clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.

AB - Alzheimer’s disease (AD) is characterized by amyloid-β (Aβ) peptide deposition in brain parenchyma as plaques and in cerebral blood vessels as cerebral amyloid angiopathy (CAA). CAA deposition leads to several clinical complications, including intracerebral hemorrhage. The underlying molecular mechanisms that regulate plaque and CAA deposition in the vast majority of sporadic AD patients remain unclear. The clusterin (CLU) gene is genetically associated with AD and CLU has been shown to alter aggregation, toxicity, and blood–brain barrier transport of Aβ, suggesting it might play a key role in regulating the balance between Aβ deposition and clearance in both brain and blood vessels. Here, we investigated the effect of CLU on Aβ pathology using the amyloid precursor protein/presenilin 1 (APP/PS1) mouse model of AD amyloidosis on a Clu+/+ or Clu−/− background. We found a marked decrease in plaque deposition in the brain parenchyma but an equally striking increase in CAA within the cerebrovasculature of APP/PS1;Clu−/− mice. Surprisingly, despite the several-fold increase in CAA levels, APP/PS1;Clu−/− mice had significantly less hemorrhage and inflammation. Mice lacking CLU had impaired clearance of Aβ in vivo and exogenously added CLU significantly prevented Aβ binding to isolated vessels ex vivo. These findings suggest that in the absence of CLU, Aβ clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.

KW - Alzheimer’s disease

KW - Aβ

KW - Cerebral amyloid angiopathy

KW - Clusterin

KW - Hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85027401907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027401907&partnerID=8YFLogxK

U2 - 10.1073/pnas.1701137114

DO - 10.1073/pnas.1701137114

M3 - Article

C2 - 28701379

AN - SCOPUS:85027401907

VL - 114

SP - E6962-E6971

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 33

ER -